Abstract: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.

Abstract: New drug delivery systems (DDS) are described containing hyaluronic acid and a therapeutic agent, wherein the therapeutic agent is linked, directly or via a linker, to 6-aminohyaluronic acid and where the linkage of the drug or linker with 6-aminohyaluronic acid is realised by an amide bond. Preferred therapeutic agents for use in the present DDS are anti-inflammatory, antibiotic, antitumor drugs. Preferred linkers are: succinic acid, succinic acid linked to aminoacids, succinic acid linked to peptides. The DDS are stable and free of undesired reaction by-products and impurities, and show a high level of pharmacological efficacy.

Abstract: A first router receives an original IS-634 standard frame formatted message over an A-bis interface from a base transceiver station. The first router identifies header information bits in the message for compression. The first router suppresses selected ones of the identified header information bits and encapsulates the message into a packet. A second router receives the packet from the first router and extracts the message from the packet. The second router reconstructs the selected ones of the header information bits that were suppressed by the first router. The second router regenerates the original IS-634 standard frame formatted message and transports the message to a base station controller over the A-bis interface.

Abstract: Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory compounds. For instance, certain short breakdown products of hCG (i.e., short peptides which can easily be synthesized, if needed modified, and used as a pharmaceutical composition) exert a major regulatory activity on pro- or anti-inflammatory cytokine cascades that are governed by a family of crucial transcription factors, the NF-?B family, which generally regulate the expression of genes involved in the body's immune response.

Abstract: Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.

Abstract: The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or MTRV (SEQ ID NO:1), AQGV (SEQ ID NO:2) or LAGV (SEQ ID NO:4).

Abstract: The present invention refers to a drug delivery system consisting of hyaluronic acid and a therapeutic active agent.

Abstract: The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing/remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing/remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-?B down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing/remitting disease as seen with multiple sclerosis.

Abstract: The invention relates to the field of transplantation medicine and to the prevention and treatment of rejection, in particular of chronic rejection, of a transplant by a recipient of the transplant. The invention provides method for modulating transplant survival in a recipient of the transplant comprising providing the transplant with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides use of a gene-regulatory peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of a transplant allowing modulating transplant survival in a recipient of the transplant.

Abstract: The invention relates to the modulation of gene expression in a cell, also called gene control, in particular, in relation to the treatment of ischemic-reperfusion injury. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof. The invention provides a method of treating ischemia-reperfusion injury in a subject by reducing NO production by the subject's macrophages, the method comprising: administering to the subject a composition comprising: means for reducing production of NO by a cell, together with a pharmaceutically acceptable excipient.

Abstract: A method and apparatus for using a 2:1 MUX to control read access, data bypass, and page size bypass in a memory array. The mechanism of the present invention reduces the 3:1 MUX normally required to manage these three functions to a 2:1 MUX.

Abstract: The invention relates to compounds exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequence AAL AAQ AAG AAV wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu; wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala; wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein AAV is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Val and Ala. In certain embodiments, the compound consists of a tripeptide selected from the group AQG, MTR, VVC, and mixtures thereof.

Abstract: Described are methods and associated means for treating a subject, such as a mammal, experiencing or thought to be at risk for hemorrhagic shock. Such methods include administering to the subject in a medically acceptable manner, a short oligopeptide such as AQGV (SEQ ID NO:1) and/or LQGV (SEQ ID NO:2).

Abstract: A food waste disposer has a housing 12 defining a grinding chamber 14 having an inlet 16 and an outlet 18. A grinding mechanism including a shredder ring 20 and a grinding disc 22, is disposed within the grinding chamber 14. A liner 21, preferably of a plastics material, extends from the shredder ring 20 to the inlet 16. The liner 21 reduces the noise generated by the disposer when in use.

Abstract: The invention relates to the field of immunology. Specifically, the invention relates to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides for an immunoregulator (IR), use of an IR in preparing a pharmaceutical composition for treating an immune-mediated disorder and a method for treating an immune-mediated disorder.

Abstract: The invention relates to compounds exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequence AAL AAQ AAG AAV wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu; wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala; wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein AAV is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Val and Ala. In one embodiment, the compound consists of a tripeptide selected from the group AQG, MTR, VVC, and mixtures thereof.

Abstract: A content addressable memory (CAM) system is disclosed including a dual mode cycle boundary latch (CBL). The CBL includes a master latch coupled to a slave latch. The CBL operates in a high speed functional mode and a lower speed test mode. In the high speed functional mode, input data bypasses the master latch and transports directly to the CBL output via the slave latch. The CBL effectively removes the master latch from the circuit in the high speed functional mode. However, in the lower speed test mode, input test data travels via both the master and slave latches to the CBL output.

Abstract: A CAM system is disclosed in which compare data, for example an address translation request, is provided as input search data to a search line generator. The search line generator presents search line input data, through a buffer, to CAM and RAM array systems that include dynamically precharged and evaluated memory cells. Timing sequences in the CAM system are controlled by a series of individually triggered one shot pulse generators. The one shot pulse generators control the timing of CAM system activities, for example the precharge of CAM subsystems, so that these activities are staggered in time. This timing approach improves power consumption and evaluation time within the CAM system. By distributing precharging activities in time throughout the CAM cycle, current peaking during the CAM cycle is reduced. The CAM system latches results in an output latch that is controlled by a one shot pulse generator.

Abstract: A process for treating ground water containing nitrogen compounds, including ammonia, urea and nitrate, is provided. The ground water is extracted downgradient of the source of contamination and mixed with a chemical oxidant to oxidize the nitrogen component to nitrogen gas. The chemical oxidant may be any suitable oxidant, including a halogenated oxidant, such as a hypochlorite, hypobromite or hypoiodite compound, and Fentons reagent, or combinations thereof. The ground water can be further treated as desired to remove residual oxidants, as well as nitrate, to provide a processed water having characteristics suitable for discharge with limited to no adverse impact on the discharge environment.